BAX vs COO — Key Metrics
| Metric | BAX (BAXTER INTERNATIONAL INC) | COO (COOPER COMPANIES INC) |
|---|---|---|
| Price | 26.16 | 60.75 |
| Market Cap | 13.53 Billion | 11.55 Billion |
| P/E (TTM) | -18.42 | 20.66 |
| P/B (Quarterly) | 1.87 | 1.449 |
| P/S (TTM) | 1.17 | 2.73 |
| Net Profit Margin (TTM) | -6.2 | 13.5 |
| Gross Margin (TTM) | 30.1 | 65.9 |
| ROE (TTM) | -11.6 | 6.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Underperform
Recommendation Summary
Stock BAX is projected to greatly outperform the market, stock COO is projected to underperform the market. Upfront Recommendation: BAX.
Financial Metrics
| BAX | Metrics | COO |
|---|---|---|
| $26.16 | Price | $60.75 |
| — | Market Capitalization | — |
| 1.17 | Price to Sales | 2.73 |
| 11.93 | Price to FCF Ratio | 17.04 |
| 3.87 | Price to Gross Profit | 4.14 |
| 26.08 | Price to R&D | 68.03 |
| 1.98 | Price to Current Assets | 5.06 |
BAX vs COO at a glance
Baxter International INC (BAX) and Cooper Companies INC (COO) are both Medical Instruments & Supplies companies in the Healthcare sector. BAX is the larger, at $13.5 billion in market value against $11.6 billion for COO, about 1.2 times the size.
On trailing-twelve-month figures, BAX trades at 1.2 times trailing sales and COO at 2.7; net profit margins are -6.2% and 13.5%.
The Upfront Investment model currently rates BAX Greatly Outperform and COO Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.